Vikse, Jens
Midtvedt, Øyvind
Fevang, Bjørg-Tilde Svanes
Garen, Torhild
Palm, Øyvind
Wallenius, Marianne
Bakland, Gunnstein
Norheim, Katrine Brække
Molberg, Øyvind
Hoffmann-Vold, Anna-Maria
Funding for this research was provided by:
University of Bergen
Article History
Received: 12 July 2023
Accepted: 28 August 2023
First Online: 5 September 2023
Declarations
:
: Written informed consent was given for the included IgG4-RD patients as requirement for inclusion in NOSVAR. The study was conducted in compliance with the Helsinki Declaration and approved by the regional ethics committee (REK #342136).
: Not applicable.
: J.V. has been a speaker/consultant of Boehringer Ingelheim, GSK, Novartis, Jupiter Life Science. B-T.S.F. has been a speaker/consultant of Lilly, UCB. G.B. has been a speaker/consultant of UCB. A-M.H-V. has been a speaker/consultant of ARXX, Boehringer Ingelheim, Genentech, Jannsen, Medscape, Merck Sharp & Dohme, Roche, and received grant from Boehringer Ingelheim, Jannsen.